Actitudes e imágenes sociales sobre el cribado de cáncer colorrectal. Una aproximación exploratoria mediante grupos de discusión / Attitudes and social images regarding colorectal cancer screening. An exploratory approach through discussion groups

Fundamentos: El programa de cribado de cáncer colorrectal (CCR) mediante el test de sangre oculta en heces (SOH) ha alcanzado una implementación elevada en España, aunque la participación sigue sin encontrarse en cifras óptimas. A su vez, los datosdisponibles ofrecen diferencias de participación significativas, tanto entre CC. AA. como entre distintos grupos sociodemográficos, loque plantea diferentes problemas de equidad. Este estudio buscó realizar un análisis exploratorio, desde una perspectiva cualitativa,sobre las actitudes, percepciones e imágenes sociales que la población objeto del cribado de cáncer colorrectal tenía sobre el mismo,así como las barreras y elementos de mejora a partir de estas. Métodos: Este estudio se diseñó mediante un enfoque de investigación cualitativa a partir de la realización de cuatro grupos dediscusión, durante el mes de mayo de 2022, a un total de veintiséis personas (igual número de hombres y mujeres) con edades decincuenta a sesenta y nueve años, residentes en la Comunidad de Madrid, Cataluña, Andalucía y País Vasco (en grandes y pequeñasciudades), con diferentes niveles formativos y distintas experiencias previas de participación en el programa de cribado de CCR. Resultados: Se detectaron distintas conceptualizaciones de la prevención, pero ninguna que englobe el cáncer (y especialmente el colorrectal) como elemento a incorporar en las prácticas cotidianas, ya que su aparición se asocia fundamentalmente al azar.Sumado al desconocimiento del CCR frente a otros tipos (mama o próstata), se percibieron diferentes barreras de carácter actitudinala la participación en un programa de cribado de CCR, como fueron el rechazo a formar parte del colectivo de más edad (diana de laprueba), el miedo a la espera por los resultados, la falta de fiabilidad o la sensación de poder postergar el momento...(AU)

Backgorund: The screening for colorectal cancer (CRC) through the fecal occult blood test (FOBT) has achieved high implementation in Spain, although participation rates are still not optimal. At the same time, available data show significant differencesin participation both among autonomous communities and among different sociodemographic groups, which raises various equityissues. This study aimed to conduct an exploratory analysis from a qualitative perspective on the attitudes, perceptions, and socialimages that the target population for colorectal cancer screenings holded regarding them, as well as the barriers and areas forimprovement identified through these. Methods: This study was designed using a qualitative research approach, through the conduct of four focus groups in May 2022, witha total of twenty-six participants (equal number of men and women) aged fifty to sixty-nine years. The participants were residents of theCommunity of Madrid, Catalonia, Andalusia, and the Basque Country (in both large and small cities), with varying educational levels anddifferent previous experiences of participation in the CRC screening program. Results: Different conceptualizations of prevention were identified, but none that encompassed cancer (especially colorectalcancer) as an element to be incorporated into daily practices since its occurrence is primarily associated with chance. In addition tothe lack of knowledge about CRC compared to other types of cancer (such as breast or prostate cancer), various attitudinal barriersto participation in the CRC screening program were perceived. These included the rejection of being part of the older age group(targeted by the test), fear of waiting for the results, lack of reliability, or the sense of being able to postpone the moment...(AU)

Perceived barriers and benefits in the participation in faecal occult blood test colorectal cancer screening programme / Barreras y beneficios percibidos en la participación en el cribado de cáncer de colon mediante test de sangre oculta en heces

Background: Colorectal cancer is the second cancer-related cause of death in the world. Tumour stage at diagnosis is the principal prognosis factor of survival. However, the participation in the programme is around 50%. The aim of the study was to identify the benefits and barriers perceived by the population when participating in a colorectal cancer screening programme with faecal occult blood test. Methods: We carried out a cases–controls study with 408 participants. We analyzed epidemiological and social variables associated with lifestyle and behavioural factors based in the Health Belief Model. We conducted a descriptive analysis, and identified variables associated to adherence by a logistic regression. Results: Variables independently associated with the participation in a colorectal cancer screening programme were age (OR 1.06; 95% CI: 1.01–1.11), having a stable partner (OR 1.96; 95% CI: 1.20–3.18), the level of education (OR 1.59; 95% CI: 1.02–2.47) and two of the barriers to participate in the faecal occult blood test screening: “you don’t know how to do one” (OR=0.46; 95% CI: 0.23–0.93) and “it is not that important right now” (OR=0.43; 95% CI: 0.24–0.78). Conclusion: The existing barriers for screening with faecal occult blood test are the best factor predicting. This is relevant when designing the intervention programmes, as they should focus on reducing perceived barriers to increase the participation in colorectal cancer screening, thereby reducing colorectal cancer mortality.(AU)

Antecedentes: El cáncer colorrectal constituye la segunda causa de muerte por cáncer en el mundo. El estadio del tumor al diagnóstico es el principal factor pronóstico de supervivencia. Sin embargo, la participación en el programa está en torno al 50%. El objetivo de este estudio fue identificar los beneficios y las barreras percibidos por la población al participar en un programa de cribado de cáncer de colon mediante el test de sangre oculta en heces. Métodos: Estudio de casos y controles con 408 participantes en el que analizamos variables sociodemográficas, variables asociadas al estilo de vida y factores conductuales basados en el Modelo de Creencias en Salud. Realizamos un análisis descriptivo y, para identificar las variables asociadas a la adhesión al programa de cribado de cáncer colorrectal, una regresión logística. Resultados: Las variables que se asociaron de forma independiente a la participación en el programa fueron la edad (OR 1,06; IC 95% 1,01-1,11), tener pareja estable (OR 1,96; IC 95% 1,20-3,18), el nivel de estudios (OR 1,59; IC 95% 1,02-2,47) y 2 de las barreras para participar en el cribado mediante test de sangre oculta en heces: «no sabe cómo hacerlo» (OR 0,46; IC 95% 0,23-0,93) y «no es un problema importante en el momento actual» (OR 0,3; IC 95% 0,24-0,78). Conclusión: Las barreras existentes para el cribado mediante test de sangre oculta en heces son el mejor factor predictivo de participación. Esto es importante a la hora de diseñar los programas de cribado de cáncer colorrectal, ya que la reducción de las barreras percibidas aumentará la participación en los mismos, reduciendo así la mortalidad por cáncer de colon.(AU)

Sangre oculta en heces en pacientes sintomáticos en Atención Primaria: Un estudio retrospectivo en el área sanitaria de Toledo / Faecal occult blood test in symptomatic patients in primary care: A retrospective study in a healthcare area of Toledo

Objetivo Revisar el protocolo de solicitud de sangre oculta en heces (SOH) en pacientes sintomáticos como prueba de derivación a colonoscopia, utilizando un punto de corte de 15μg Hb/g heces en 3 muestras consecutivas y comparar su utilidad con las recomendaciones actuales de un punto de corte de 10μg Hb/g heces en una muestra. Material y métodos Estudio observacional retrospectivo centrado en las peticiones de la prueba de SOH en pacientes sintomáticos en Atención Primaria. Las muestras fueron analizadas en el servicio de laboratorio durante el año 2017. En el análisis de datos se incluyeron 715 pacientes con la prueba de SOH positiva y 925 pacientes con resultado negativo. Se realizó un análisis descriptivo de los resultados de SOH, motivo de solicitud y colonoscopia, junto con el estudio de la utilidad diagnóstica de la prueba SOH para los puntos de corte de 10 y 15μg Hb/g heces en la misma población. Resultados La tasa de positividad de la prueba fue del 22,8% y la tasa de detección de cáncer colorrectal fue del 11%. El número de muestras no modifica la precisión diagnóstica. El valor predictivo negativo es superior con el punto de corte de 10μg Hb/g heces. Conclusione La selección correcta de pacientes y del punto de corte óptimo aumentan la tasa de detección de cáncer colorrectal. El cambio de protocolo de 10μg Hb/g heces y la recogida de una muestra para pacientes sintomáticos desde Atención Primaria mejoran la utilidad de la prueba SOH (AU)

Aim To review referral protocol in symptomatic patients from primary care of using 15μgHb/g faeces threshold with three consecutive samples in faecal occult blood (FOB) test. To compare test utility using current recommendations of 10μgHb/g faeces threshold and one sample. Material and methods A retrospective observational study was designed, including FOB samples of symptomatic patients from primary care. Samples were analyzed at the biochemistry laboratory in 2017. Seven hundred and fifteen patients tested positive and 925 patients negative. Exclusion criteria were secondary care request and patients under the age of 18. Descriptive analysis was performed of FOB results and clinical data about request and colonoscopy. FOB test's diagnostic utility was studied for different threshold (10 and 15μgHb/g faeces) in the same population. Results FOB positivity rate was 22.8% and cancer detection rate was 11%. However, the number of samples does not modify diagnostic precision. Negative predictive value is higher with 10μgHb/g faeces threshold. Conclusions Correct patient selection and optimal threshold increase cancer detection rate. The protocol with 10μgHb/g faeces threshold and one sample collection for symptomatic patients from primary care improves the FOB test's purpose (AU)

Tests de diagnòstic ràpid digestiu: gastroenteritis agudes víriques, bacterianes I parasitàries. Helicobacter pylori.Marcadors inflamatoris intestinals / No disponible

No disponible

Adenocarcinoma de colon sobre adenoma serrado tradicional / No disponible

No disponible

Utilidad del test de sangre oculta en heces para el diagnóstico del cáncer colorrectal en la práctica clínica en atención primaria / Utility of faecal occult blood test for the diagnosis of colorectal cancer in clinical practice in primary care

No disponible

Small bowel enteroscopy - A joint clinical guideline by the Spanish and Portuguese small-bowel study groups

The present evidence-based guidelines are focused on the use of device-assisted enteroscopy in the management of small-bowel diseases. A panel of experts selected by the Spanish and Portuguese small-bowel study groups reviewed the available evidence focusing on the main indications of this technique, its role in the management algorithm of each indication, and its diagnostic and therapeutic yield. A set of recommendations was issued accordingly

No disponible

Carcinoma de células en anillo de sello sobre pólipo juvenil / No disponible

No disponible

Mastocitosis sistémica diagnosticada endoscópicamente / Endoscopically diagnosed systemic mastocytosis

No disponible

Impacto de un programa de cribado poblacional basado en detección de sangre oculta en heces sobre el manejo quirúrgico del cáncer colorrectal / Impact of a population screening program based on fecal occult blood detection on the surgical management of colorectal cancer

OBJETIVO PRINCIPAL: comparar los pacientes intervenidos de CCR (Cáncer colorrectal) en el contexto de un programa de cribado poblacional versus aquellos diagnosticados por presentar síntomas. METODOLOGÍA: estudio longitudinal retrospectivo. Se estudiaron dos cohortes de pacientes intervenidos de CCR en el Hospital Clínico de Barcelona (2010-2012) procedentes del Programa de detección precoz de CCR de Barcelona (n = 59), y de Urgencias o de Consultas Externas por presentar sintomatología (n = 118). RESULTADOS PRINCIPALES: Los del grupo cribado presentaron con mayor frecuencia tumores en estadio precoz (estadios I-II) que el grupo síntomas (57,6% vs 23,7%; p < 0,001). La necesidad de uso de ostomía, y la estancia hospitalaria fue superior en el grupo síntomas (36,4% vs 10,2%; p = 0,001; 10,1 días vs 7,1 días; p < 0,001. CONCLUSIÓN PRINCIPAL: los pacientes con CCR diagnosticados en el contexto de programas de cribado presentan un estadio más precoz, menor estancia hospitalaria y menor necesidad de ostomías. El programa de cribado poblacional presenta beneficios para los pacientes y el sistema sanitario

OBJECTIVE: the comparison of patients diagnosed in a screening program versus those diagnosed by symptoms has not been studied in depth. The aim of this study is to compare patients diagnosed with CRC in the context of a population-based screening program and those diagnosed only by symptoms. METHODS: longitudinal retrospective study in which two cohorts of patients with CRC are compared between 2010 and 2012 at Hospital Clinic de Barcelona depending on the method of diagnosis. Fifty-nine patients diagnosed by the cancer screening programme of Barcelona were compared with 118 patients diagnosed only by symptoms at the emergency room or outpatient clinic. RESULTS: Patients in the screened group presented more frequently tumors in the early stage (stages I-II) compared with the symptom group (57.6% vs. 23.7%, p < 0.001). The need for ostomy was higher in the symptom group, (36, 4% vs 10,2%, p = 0.001). Hospital stay was higher in the group diagnosed only by symptoms (10.1 days vs 7.1 days, p < 0.001). CONCLUSIONS: Patients with CRC diagnosed in the context of screening programmes have an earlier stage, shorter hospital stay and less need for ostomy. In conclusion, the population screening program, beyond the reduction of delayed diagnosed and mortality, directly benefits CRC patients and decreases Hospital costs

Cribado poblacional de cáncer colorrectal: cánceres de intervalo y relación con el resultado cuantitativo del test inmunológico de sangre oculta en heces / Population-based colorectal cancer screening: Interval cancers and relationship with the quantitative faecal immunological for hemoglobin

Introducción y objetivo: La sensibilidad de los programas de cribado de cáncer colorrectal determina su efectividad y está directamente relacionada con el cáncer de intervalo (CI). Este estudio describe la frecuencia y las características de los CI del Programa de la ciudad de Barcelona y analiza su relación con el valor cuantitativo del test de cribado previo (FIT). Material y métodos: Se incluyen los CI tras FIT negativo de las primeras dos rondas del Programa (2010-2013); periodo de observación hasta julio de 2017. La fuente de información de los CI es su notificación por profesionales y pacientes y el cruce de bases de datos hospitalarias y CMBD. Resultados: La sensibilidad del Programa es del 82%. Los CI se diagnostican más en colon proximal y recto y en estadios avanzados que los cánceres de cribado, y presentan valores FIT más elevados que el conjunto de personas con FIT negativo. Conclusiones: La sensibilidad obtenida es aceptable y comparable a la de otros programas. El valor cuantitativo del FIT en personas con test negativo debería incluirse en las estrategias de personalización del cribado para reducir el riesgo de CI

Introduction and objective: The sensitivity of colorectal cancer screening programmes determines their effectiveness and is directly related to the interval cancer (IC). This study describes the frequency and characteristics of the IC of the Programme of Barcelona, Spain, and analyses its relationship with the quantitative value of the screening test (FIT). Material and methods: ICs after negative FIT of the first two rounds of the Programme (2010-2013) were included, observation period until July 2017. The information source of the ICs was their notification by professionals and patients, hospital databases and CMBD (Spanish Minimum Basic Data Set). Results: The sensitivity of the Programme is 82%. ICs are diagnosed more in proximal and rectal colon and in advanced stages than screening cancers, and have higher FIT values than overall people with negative FIT. Conclusions: The sensitivity is acceptable and comparable to that of other programmes. The quantitative value of FIT in people with negative test should be included in the personalisation strategies of screening to reduce the risk of IC

Marcadores de actividad en la enfermedad inflamatoria intestinal / Use of biomarkers in inflammatory bowel disease

Existe una gran variedad de marcadores útiles tanto en el diagnóstico como en el seguimiento de la enfermedad inflamatoria intestinal. Clásicamente se han utilizado los serológicos, ampliamente distribuidos y accesibles, pero en los últimos años han cobrado importancia los fecales, en especial la calprotectina fecal, por haber demostrado mayor precisión a la hora tanto de establecer la sospecha de la enfermedad como de predecir la curación mucosa o la persistencia de actividad inflamatoria. La calprotectina fecal muestra buena capacidad para predecir estudios endoscópicos patológicos, pero tiene una especificidad limitada ya que puede alterarse en otros cuadros digestivos con síntomas similares. La calprotectina fecal presenta mayor precisión cuando se asocia a otros parámetros, en especial a la proteína C reactiva, y a escalas clínicas de actividad inflamatoria. Finalmente, hay múltiples marcadores de nueva generación, serológicos y fecales, de los que hay escasa evidencia, aunque algunos han mostrado resultados prometedores en diferentes estudios

There are many useful biomarkers for initial diagnosis and the management of inflammatory bowel disease. Serologic biomarkers have been traditionally used because they are widely disposable, but recently faecal biomarkers, especially faecal calprotectin, have acquired great importance as they have shown to be more precise when establishing suspicion of the disease and also as predictors of mucosal healing or persistence of inflammatory activity. Faecal calprotectin is a good tool for predicting abnormal endoscopic studies, but has limited specificity because its levels can be altered in many digestive diseases presenting with similar symptoms. The precision of faecal calprotectin is higher when associated with other altered parameters, especially with C-reactive protein, or with clinical scores of inflammatory activity. Finally, there are many new generation serologic and faecal biomarkers. Despite there not being much evidence about these yet, some of them have shown promising results in different studies

Colorectal penetration by two intrauterine devices

No disponible

Pólipo de Nakamura: un hallazgo endoscópico infrecuente / Nakamura polyp: An unusual endoscopic finding

No disponible

Programa de cribado poblacional de cáncer colorrectal en Aragón. Primeros resultados / Colorectal cancer screening programme in Aragon (Spain): preliminary results

Objetivo: Describir los primeros resultados del programa de cribado de cáncer colorrectal en Aragón para valorar su implantación. Métodos: Se recogen los datos del programa en el primer año de implantación (2014), basado en la realización de test de sangre oculta en heces inmunoquímico para personas de 60-69 años de edad. Se reportan los indicadores principales de la red nacional de cribado. Resultados: Población invitada tras exclusiones: 12.518 personas. Tasa de participación: 45,28% (intervalo de confianza del 95% [IC95%]: 44,41-46,15). Test inadecuados: 0,21% (IC95%: 0,12-0,37). Test positivos: 10,75% (IC95%: 9,97-11,58). Aceptación de colonoscopia: 95,07% (IC95%: 93,04-96,52). Colonoscopias completas: 97,58% (IC95%: 95,98-98,55). Tasas de detección de adenomas de alto riesgo: 14,7‰ (IC95%: 11.9-18.2); adenomas de bajo riesgo: 5,55‰ (IC95%: 3,9-7,8). Valor predictivo positivo (VVP) para cualquier adenoma: 58,55% (IC95%: 54,49-62,49); VVP para cáncer invasivo: 5,36% (IC95%: 3,8-7,51). Conclusión: El análisis de los indicadores muestra que el programa se está implantando de forma adecuada

Objective: To describe preliminary findings from the colorectal cancer screening programme in Aragon (Spain) to evaluate its implementation. Methods: We have collected data from the first year of the program (2014) based on faecal occult blood immunochemical (FOBTi) test in patients 60-69 years old. We report "indicators" defined by the "Red Nacional de Cribado". Results: Invited population after exclusions: 12,518. Program participation rate: 45.28% (95%CI: 44.41-46.15). Inadequate tests: 0.21% (95%CI: 0.12-0.37); positive FOBTi test 10.75% (95%CI: 9.97-11.58) and colonoscopy acceptance 95.07% (95%CI: 93.04-96.52). Colonoscopy was appropriate and complete in 97.58% (95%CI: 95.98-98.55) of cases. The high- and low-risk adenoma detection rates were 14.7‰ (95%CI: 11.9-18.2) and 5.55‰ (95%CI: 3.9-7.8) respectively. The positive predictive value for any adenoma was 58.55% (95%CI: 54.49-62.49) and for invasive cancer was 5.36% (95%CI: 3.8-7.51). Conclusion: The indicator analysis of the ongoing programme suggests the programme is being implemented correctly in our community

Cribado del cáncer colorrectal y supervivencia / Colorectal cancer screening and surviva

No disponible

El reto del colon derecho / The right colon challenge

No disponible

Capsule endoscopy with PillCamSB2 versus PillCamSB3: has the improvement in technology resulted in a step forward?

Aim: To compare the findings and completion rate of Pill-Cam® SB2 and SB3. Methods: This was a retrospective single-center study that included 357 consecutive small bowel capsule endoscopies (SBCE), 173 SB2 and 184 SB3. The data collected included age, gender, capsule type (PillCam® SB2 or SB3), quality of bowel preparation, completion of the examination, gastric and small bowel transit time, small bowel findings, findings in segments other than the small bowel and the detection of specific anatomical markers, such as the Z line and papilla. Results: The mean age of the patients was 48 years and 66.9% were female. The two main indications were suspicion/staging of inflammatory bowel disease (IBD) and obscure gastrointestinal bleeding (OGIB) (43.7% and 40.3%, respectively). Endoscopic findings were reported in 76.2% of examinations and 53.5% were relevant findings. No significant differences were found between SB2 and SB3 with regard to completion rate (93.6% vs 96.2%, p = 0.27), overall endoscopic findings (73.4% vs 78.8%, p = 0.23), relevant findings (54.3% vs 52.7%, p = 0.76), first tertile findings (43.9% vs 48.9%, p = 0.35), extra-SB findings (23.7% vs 17.3%, p = 0.14), Z line and papilla detection rate (35.9% vs 35.7%, p = 0.97 and 27.1% vs 32.6%, p = 0.32, respectively). With regard to the patient subgroups with suspicion/staging of IBD, significant differences were found in relation to the detection of villous edema and the 3rd tertile findings, thus favoring SB3 (26.3% vs 43.8%, p = 0.02 and 47.4% vs 66.3%, p = 0.02, respectively). Mucosal atrophy was significantly more frequently diagnosed with the PillCam® SB3 in patients with anemia/OGIB (0% vs 8%, p = 0.03). Conclusions: Overall, PillCam® SB3 did not improve the diagnostic yield compared to SB2, although it improved the detection of villous atrophy and segmental edema (AU)

No disponible

Short-term outcome of patients with colon cancer diagnosed by symptoms and screening

No disponible

The impact of screening on short-term outcome after surgery for colorectal cancer

Aim: To investigate the influence of a screening program on the short-term outcome of patients undergoing surgery for colorectal cancer. Methods: Between April 2010 and December 2012 patients diagnosed with colorectal cancer via the screening program (n = 80) were compared with patients diagnosed elsewhere (n = 106). Only patients of ≥ 50 and ≤ 69 years of age diagnosed outside the program were selected as controls. The clinical variables included age, sex, American Society of Anesthesiologists (ASA) status, Charlson index, preoperative hemoglobin and serum albumin levels, surgical approach, tumor location and stage, perioperative transfusion and postoperative morbidity. A multivariate analysis was used to identify variables independently associated with outcome. Results: There were no significant differences with regard to age, sex and ASA status. Preoperative hemoglobin (14.1 ± 1.6 g/ dl vs 12.3 ± 2.3 g/dl; p < 0.001) and serum albumin (4.45 ± 0.26 g/dl vs 4.0 ± 0.6 g/dl; p < 0.001) levels were significantly higher in the screening group. The overall morbidity was significantly lower in the screening group (38.8% vs 63.2; p < 0.001) and mainly related to a higher rate of Clavien-Dindo grade II complications in controls. There were no differences with regard to wound infection, postoperative ileus, anastomotic leakage or reoperations. The median length of hospital stay was shorter in the screening group (6 vs 9 days; p = 0.003). Multivariate analysis showed that diagnosis outside the screening program, type of surgical procedure, open surgery and Charlson index were independent risk factors for postoperative complications. Conclusions: The diagnosis of colorectal cancer via the screening program is associated with a lower rate of postoperative minor complications and a shorter hospital stay (AU)

No disponible